Skip to content
lifestyle.easyhouseremodeling.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Longeveron
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)
June 18, 2026
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
May 13, 2026
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
May 11, 2026
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
May 8, 2026
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
May 5, 2026
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
April 8, 2026
Longeveron Announces Private Placement of up to $30 Million
March 12, 2026
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
March 9, 2026
←
Previous Page
1
2